Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2019

Open Access 01-12-2019 | Hypertension | Research

Prevalence and clinical characteristics of hypertension and metabolic syndrome in newly diagnosed patients with ketosis-onset diabetes: a cross-sectional study

Authors: Jun-Wei Wang, Ai-Ping Wang, Ming-Yun Chen, Jun-Xi Lu, Jiang-Feng Ke, Lian-Xi Li, Wei-Ping Jia

Published in: Diabetology & Metabolic Syndrome | Issue 1/2019

Login to get access

Abstract

Background

To investigate the prevalence and clinical characteristics of hypertension (HTN) and metabolic syndrome (MetS) in newly diagnosed diabetes with ketosis-onset.

Methods

A cross-sectional study was adopted in 734 newly diagnosed diabetics including 83 type 1 diabetics with positive islet-associated autoantibodies, 279 ketosis-onset diabetics without islet-associated autoantibodies and 372 non-ketotic type 2 diabetics. The clinical characteristics of HTN and MetS were compared across the three groups, and the risk factors of them were appraised in each group.

Results

The prevalence of HTN and MetS were substantially higher in the ketosis-onset diabetics (34.4% for HTN and 58.8% for MetS) than in the type 1 diabetics (15.7% for HTN, P = 0.004; 25.3% for MetS, P < 0.001), but showed no remarkable difference compared with the type 2 diabetics (42.7% for HTN, P = 0.496; 72.3% for MetS, P = 0.079). Furthermore, the risk factors for both HTN and MetS in the ketosis-onset diabetics resembled those in the type 2 diabetics, but significantly different from those in the type 1 diabetics.

Conclusions

The prevalence of HTN and MetS in the ketosis-onset diabetics were magnificently higher than in the type 1 diabetics but showed no difference in comparison to the type 2 diabetics. Likewise, the clinical features and risk factors of HTN and MetS in the ketosis-onset diabetes resembled those in the type 2 diabetes but differed from those in the type 1 diabetes. Our findings indicate that ketosis-onset diabetes should be classified into type 2 diabetes rather than idiopathic type 1 diabetes.
Literature
1.
go back to reference Mauvaisjarvis F, Sobngwi E, Porcher R, et al. Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance. Diabetes. 2004;53(3):645.CrossRef Mauvaisjarvis F, Sobngwi E, Porcher R, et al. Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance. Diabetes. 2004;53(3):645.CrossRef
2.
go back to reference Mbanya J, Motala AA. The lancet seminar: diabetes in sub-Saharan Africa. Lancet. 2010;371(9628):1927–35. Mbanya J, Motala AA. The lancet seminar: diabetes in sub-Saharan Africa. Lancet. 2010;371(9628):1927–35.
3.
go back to reference American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Supplement 1):S13–27.CrossRef American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Supplement 1):S13–27.CrossRef
4.
go back to reference Gosmanov AR, Gosmanov NR. Advancing clinical care for the patients with ketosis-prone diabetes: from knowledge to action. J Diabetes Complications. 2015;29(7):853.CrossRef Gosmanov AR, Gosmanov NR. Advancing clinical care for the patients with ketosis-prone diabetes: from knowledge to action. J Diabetes Complications. 2015;29(7):853.CrossRef
5.
go back to reference Umpierrez GE. Ketosis-prone type 2 diabetes: time to revise the classification of diabetes. Diabetes Care. 2006;29(12):2755–7.CrossRef Umpierrez GE. Ketosis-prone type 2 diabetes: time to revise the classification of diabetes. Diabetes Care. 2006;29(12):2755–7.CrossRef
6.
go back to reference Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 2006;144(5):350.CrossRef Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 2006;144(5):350.CrossRef
7.
go back to reference Lontchi-Yimagou E, Boudou P, Nguewa JL, et al. Acute phase ketosis-prone atypical diabetes is associated with a pro-inflammatory profile: a case-control study in a sub-Saharan African population. J Diabetes Metab Disord. 2018;17:37–43.CrossRef Lontchi-Yimagou E, Boudou P, Nguewa JL, et al. Acute phase ketosis-prone atypical diabetes is associated with a pro-inflammatory profile: a case-control study in a sub-Saharan African population. J Diabetes Metab Disord. 2018;17:37–43.CrossRef
8.
go back to reference Nalini R, Gaur LK, Maldonado M, et al. HLA class II alleles specify phenotypes of ketosis-prone diabetes. Diabetes Care. 2008;31:1195–200.CrossRef Nalini R, Gaur LK, Maldonado M, et al. HLA class II alleles specify phenotypes of ketosis-prone diabetes. Diabetes Care. 2008;31:1195–200.CrossRef
9.
go back to reference Balti EV, Ngo-Nemb MC, Lontchi-Yimagou E, et al. Association of HLA class II markers with autoantibody-negative ketosis-prone atypical diabetes compared to type 2 diabetes in a population of sub-Saharan African patients. Diabetes Res Clin Pract. 2015;107:31–6.CrossRef Balti EV, Ngo-Nemb MC, Lontchi-Yimagou E, et al. Association of HLA class II markers with autoantibody-negative ketosis-prone atypical diabetes compared to type 2 diabetes in a population of sub-Saharan African patients. Diabetes Res Clin Pract. 2015;107:31–6.CrossRef
10.
go back to reference Li MF, Ren Y, Zhao CC, et al. Prevalence and clinical characteristics of lower limb atherosclerotic lesions in newly diagnosed patients with ketosis-onset diabetes: a cross-sectional study. Diabetol Metab Syndr. 2014;6:71.CrossRef Li MF, Ren Y, Zhao CC, et al. Prevalence and clinical characteristics of lower limb atherosclerotic lesions in newly diagnosed patients with ketosis-onset diabetes: a cross-sectional study. Diabetol Metab Syndr. 2014;6:71.CrossRef
11.
go back to reference Li LX, Zhao CC, Ren Y, et al. Prevalence and clinical characteristics of carotid atherosclerosis in newly diagnosed patients with ketosis-onset diabetes: a cross-sectional study. Cardiovasc Diabetol. 2013;12:18.CrossRef Li LX, Zhao CC, Ren Y, et al. Prevalence and clinical characteristics of carotid atherosclerosis in newly diagnosed patients with ketosis-onset diabetes: a cross-sectional study. Cardiovasc Diabetol. 2013;12:18.CrossRef
12.
go back to reference Li TT, Wang AP, Lu JX, et al. Prevalence and clinical characteristics of non-alcoholic fatty liver disease in newly diagnosed patients with ketosis-onset diabetes. Diabetes Metab. 2018;44(5):437–43.CrossRef Li TT, Wang AP, Lu JX, et al. Prevalence and clinical characteristics of non-alcoholic fatty liver disease in newly diagnosed patients with ketosis-onset diabetes. Diabetes Metab. 2018;44(5):437–43.CrossRef
13.
go back to reference Coats AJ, Cruickshank JM. Hypertensive subjects with type-2 diabetes, the sympathetic nervous system, and treatment implications. Int J Cardiol. 2014;174(3):702–9.CrossRef Coats AJ, Cruickshank JM. Hypertensive subjects with type-2 diabetes, the sympathetic nervous system, and treatment implications. Int J Cardiol. 2014;174(3):702–9.CrossRef
14.
15.
go back to reference Lastra G, Syed S, Kurukulasuriya LR, Manrique C, Sowers JR. Type 2 diabetes mellitus and hypertension: an update. Endocrinol Metab Clin North Am. 2014;43(1):103–22.CrossRef Lastra G, Syed S, Kurukulasuriya LR, Manrique C, Sowers JR. Type 2 diabetes mellitus and hypertension: an update. Endocrinol Metab Clin North Am. 2014;43(1):103–22.CrossRef
16.
go back to reference Chillaron JJ, Flores LJA, Benaiges D, et al. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism. 2014;63(2):181–7.CrossRef Chillaron JJ, Flores LJA, Benaiges D, et al. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism. 2014;63(2):181–7.CrossRef
17.
go back to reference Chillaron JJ, Sales MP, Flores-Le-Roux JA, et al. Insulin resistance and hypertension in patients with type 1 diabetes. J Diabetes Complications. 2011;25(4):232–6.CrossRef Chillaron JJ, Sales MP, Flores-Le-Roux JA, et al. Insulin resistance and hypertension in patients with type 1 diabetes. J Diabetes Complications. 2011;25(4):232–6.CrossRef
18.
go back to reference Tan H, Zhou Y, Yu Y. Characteristics of diabetic ketoacidosis in Chinese adults and adolescents—a teaching hospital-based analysis. Diabetes Res Clin Pract. 2012;97(2):306–12.CrossRef Tan H, Zhou Y, Yu Y. Characteristics of diabetic ketoacidosis in Chinese adults and adolescents—a teaching hospital-based analysis. Diabetes Res Clin Pract. 2012;97(2):306–12.CrossRef
19.
go back to reference Lontchi-Yimagou E, Nguewa JL, Assah F, et al. Ketosis-prone atypical diabetes in Cameroonian people with hyperglycaemic crisis: frequency, clinical and metabolic phenotypes. Diabet Med. 2017;34(3):426–31.CrossRef Lontchi-Yimagou E, Nguewa JL, Assah F, et al. Ketosis-prone atypical diabetes in Cameroonian people with hyperglycaemic crisis: frequency, clinical and metabolic phenotypes. Diabet Med. 2017;34(3):426–31.CrossRef
20.
go back to reference Lu H, Hu F, Zeng Y, et al. Ketosis onset type 2 diabetes had better islet beta-cell function and more serious insulin resistance. J Diabetes Res. 2014;2014:510643.CrossRef Lu H, Hu F, Zeng Y, et al. Ketosis onset type 2 diabetes had better islet beta-cell function and more serious insulin resistance. J Diabetes Res. 2014;2014:510643.CrossRef
21.
go back to reference Zhang M, Li Y, Cui W, et al. The clinical and metabolic characteristics of young-onset ketosis-prone type 2 diabetes in China. Endocr Pract. 2015;21:1364–71.CrossRef Zhang M, Li Y, Cui W, et al. The clinical and metabolic characteristics of young-onset ketosis-prone type 2 diabetes in China. Endocr Pract. 2015;21:1364–71.CrossRef
22.
go back to reference Hawa MI, Thivolet C, Mauricio D, et al. Metabolic syndrome and autoimmune diabetes: action LADA 3. Diabetes Care. 2009;32(1):160–4.CrossRef Hawa MI, Thivolet C, Mauricio D, et al. Metabolic syndrome and autoimmune diabetes: action LADA 3. Diabetes Care. 2009;32(1):160–4.CrossRef
23.
go back to reference Li MF, Feng QM, Li LX, et al. High-normal urinary albumin-to-creatinine ratio is independently associated with metabolic syndrome in Chinese patients with type 2 diabetes mellitus: a cross-sectional community-based study. J Diabetes Investig. 2015;6(3):354–9.CrossRef Li MF, Feng QM, Li LX, et al. High-normal urinary albumin-to-creatinine ratio is independently associated with metabolic syndrome in Chinese patients with type 2 diabetes mellitus: a cross-sectional community-based study. J Diabetes Investig. 2015;6(3):354–9.CrossRef
24.
go back to reference Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008;371(9628):1927–35.CrossRef Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008;371(9628):1927–35.CrossRef
25.
go back to reference O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015;16(1):1–12.CrossRef O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015;16(1):1–12.CrossRef
26.
go back to reference Schlaich M, Straznicky N, Lambert E, et al. Metabolic syndrome: a sympathetic disease. Lancet Diabetes Endocrinol. 2015;3(2):148–57.CrossRef Schlaich M, Straznicky N, Lambert E, et al. Metabolic syndrome: a sympathetic disease. Lancet Diabetes Endocrinol. 2015;3(2):148–57.CrossRef
27.
go back to reference McGill M, Molyneaux L, Twigg SM, et al. The metabolic syndrome in type 1 diabetes: does it exist and does it matter. J Diabetes Complications. 2008;22(1):18–23.CrossRef McGill M, Molyneaux L, Twigg SM, et al. The metabolic syndrome in type 1 diabetes: does it exist and does it matter. J Diabetes Complications. 2008;22(1):18–23.CrossRef
28.
go back to reference Li LX, Dong XH, Li MF, et al. Serum uric acid levels are associated with hypertension and metabolic syndrome but not atherosclerosis in Chinese inpatients with type 2 diabetes. J Hypertens. 2015;33(3):482–90 (Discussion 490).CrossRef Li LX, Dong XH, Li MF, et al. Serum uric acid levels are associated with hypertension and metabolic syndrome but not atherosclerosis in Chinese inpatients with type 2 diabetes. J Hypertens. 2015;33(3):482–90 (Discussion 490).CrossRef
29.
go back to reference Chen MY, Zhao CC, Li TT, et al. Serum uric acid levels are associated with obesity but not cardio-cerebrovascular events in Chinese inpatients with type 2 diabetes. Sci Rep. 2017;7:40009.CrossRef Chen MY, Zhao CC, Li TT, et al. Serum uric acid levels are associated with obesity but not cardio-cerebrovascular events in Chinese inpatients with type 2 diabetes. Sci Rep. 2017;7:40009.CrossRef
30.
go back to reference Wang X, Tan H. Male predominance in ketosis-prone diabetes mellitus. Biomed Rep. 2015;3(4):439–42.CrossRef Wang X, Tan H. Male predominance in ketosis-prone diabetes mellitus. Biomed Rep. 2015;3(4):439–42.CrossRef
31.
go back to reference Lebovitz HE, Banerji MA. Ketosis-prone diabetes (flatbush diabetes): an emerging worldwide clinically important entity. Curr Diab Rep. 2018;18:120.CrossRef Lebovitz HE, Banerji MA. Ketosis-prone diabetes (flatbush diabetes): an emerging worldwide clinically important entity. Curr Diab Rep. 2018;18:120.CrossRef
32.
go back to reference Smiley D, Chandra P, Umpierrez GE. Update on diagnosis, pathogenesis and management of ketosis-prone Type 2 diabetes mellitus. Diabetes Manag (Lond). 2011;1(6):589–600.CrossRef Smiley D, Chandra P, Umpierrez GE. Update on diagnosis, pathogenesis and management of ketosis-prone Type 2 diabetes mellitus. Diabetes Manag (Lond). 2011;1(6):589–600.CrossRef
33.
go back to reference Pinero-Pilona A, Litonjua P, Aviles-Santa L, et al. Idiopathic type 1 diabetes in Dallas, Texas: a 5-year experience. Diabetes Care. 2001;24(6):1014–8.CrossRef Pinero-Pilona A, Litonjua P, Aviles-Santa L, et al. Idiopathic type 1 diabetes in Dallas, Texas: a 5-year experience. Diabetes Care. 2001;24(6):1014–8.CrossRef
34.
go back to reference Bhalla A, Noble-Bell G, Malik R, et al. Insulin requirements in patients with ketosis-prone Type 2 diabetes presenting acutely to an urban diabetes centre. Diabet Med. 2018;35:136. Bhalla A, Noble-Bell G, Malik R, et al. Insulin requirements in patients with ketosis-prone Type 2 diabetes presenting acutely to an urban diabetes centre. Diabet Med. 2018;35:136.
35.
go back to reference Maahs DM, Kinney GL, Wadwa P, et al. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care. 2005;28(2):301–6.CrossRef Maahs DM, Kinney GL, Wadwa P, et al. Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care. 2005;28(2):301–6.CrossRef
36.
go back to reference Goodstein G, Milanesi A, Weinreb JE. Ketosis-prone type 2 diabetes in a veteran population. Diabetes Care. 2014;37(4):e74–5.CrossRef Goodstein G, Milanesi A, Weinreb JE. Ketosis-prone type 2 diabetes in a veteran population. Diabetes Care. 2014;37(4):e74–5.CrossRef
37.
go back to reference Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380(9841):601–10.CrossRef Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380(9841):601–10.CrossRef
38.
go back to reference Bruno G, Merletti F, Biggeri A, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care. 2004;27(11):2689–94.CrossRef Bruno G, Merletti F, Biggeri A, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care. 2004;27(11):2689–94.CrossRef
39.
go back to reference Otiniano ME, Balasubramanyam A, Maldonado M. Presence of the metabolic syndrome distinguishes patients with ketosis-prone diabetes who have a Type 2 diabetic phenotype. J Diabetes Complications. 2005;19(6):313–8.CrossRef Otiniano ME, Balasubramanyam A, Maldonado M. Presence of the metabolic syndrome distinguishes patients with ketosis-prone diabetes who have a Type 2 diabetic phenotype. J Diabetes Complications. 2005;19(6):313–8.CrossRef
40.
go back to reference Ramos-Roman MA, Pinero-Pilona A, Adams-Huet B, et al. Comparison of type 1, type 2, and atypical ketosis-prone diabetes at 4 years of diabetes duration. J Diabetes Complications. 2006;20(3):137–44.CrossRef Ramos-Roman MA, Pinero-Pilona A, Adams-Huet B, et al. Comparison of type 1, type 2, and atypical ketosis-prone diabetes at 4 years of diabetes duration. J Diabetes Complications. 2006;20(3):137–44.CrossRef
41.
go back to reference Xie XJ, Hu Y, Cheng C, et al. Should diabetic ketosis without acidosis be included in ketosis-prone type 2 diabetes mellitus? Diabetes Metab Res Rev. 2014;30(1):54–9. CrossRefPubMed Xie XJ, Hu Y, Cheng C, et al. Should diabetic ketosis without acidosis be included in ketosis-prone type 2 diabetes mellitus? Diabetes Metab Res Rev. 2014;30(1):54–9. CrossRefPubMed
Metadata
Title
Prevalence and clinical characteristics of hypertension and metabolic syndrome in newly diagnosed patients with ketosis-onset diabetes: a cross-sectional study
Authors
Jun-Wei Wang
Ai-Ping Wang
Ming-Yun Chen
Jun-Xi Lu
Jiang-Feng Ke
Lian-Xi Li
Wei-Ping Jia
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2019
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-019-0426-x

Other articles of this Issue 1/2019

Diabetology & Metabolic Syndrome 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.